Contact
Please use this form to send email to PR contact of this press release:
Nabriva Achieves 60% Randomization Target in LEAP 1 Phase 3 Trial in Community Acquired Bacterial Pneumonia
TO:
Please use this form to send email to PR contact of this press release:
Nabriva Achieves 60% Randomization Target in LEAP 1 Phase 3 Trial in Community Acquired Bacterial Pneumonia
TO: